Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Lymphoid 2Plasma cell 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × obatoclax × Dermatologic × Clear all
NCT00724841 2016-07-22

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡